ABOS
Acumen Pharmaceuticals, Inc.
$2.37
0.00%
$171.2M
No data for this timeframe.
Vol
Market Cap$171.2M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (92%)
Inst. Holders38 funds
Inst. Value$77.5M
Inst. Activity9 buys / 3 sells
Insider Activity0B / 2S
Insider Net $-$21.1K
Reddit Sentiment60° Warm
SEC Reports3
Press Releases3
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001576885·Prev Close $2.37
Recent Activity
Jun 9, 2026
Insider
Fountain Nathan B sold 6,400 shares
Director @ $2.23 ($14.3K)
Jun 3, 2026
Insider
RA CAPITAL MANAGEMENT, L.P. was granted 35,500 shares
Director
Jun 3, 2026
Insider
RA CAPITAL MANAGEMENT, L.P. was granted 53,250 shares
Director
May 12, 2026
SEC
Acumen Pharmaceuticals reported Q1 2026 results with a net loss of $20.7M ($0.33/share), narrower than the $28.8M loss (
8-K — Impact 3/10
May 12, 2026
SEC
Acumen Pharmaceuticals reported Q1 2026 EPS of -$0.33 (GAAP) vs consensus of -$0.46, a 28.3% beat, with net loss narrowi
PRESS-RELEASE — Impact 5/10
May 12, 2026
earnings
Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights
<p>NEWTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?
Mar 26, 2026
SEC
Acumen Pharmaceuticals filed an S-3 shelf registration to register the resale of up to 10,833,331 shares of common stock
S-3 — Impact 5/10
Inst.
RA CAPITAL MANAGEMENT, L.P. — ADD
20,992,669 shares ($49.5M)
Price Targets
$7.40
+212.2% upside
Strong Buy
Current $2.37
Low $4.00
Median $8.00
High $10.00
5 analysts
$4.00
$10.00
Analyst Ratings
6Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 26, 2026 | BTIG | REITERATE | Buy → Buy |
| Mar 16, 2026 | BTIG | MAINTAIN | Buy → Buy |
| Jan 27, 2026 | BTIG | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.41 ▲ +11.9% | $-0.49 — $-0.32 | 40% YoY | 3 |
| Next Q | $-0.42 ▲ +3.8% | $-0.51 — $-0.33 | 4% YoY | 3 |
| Current FY | $-1.58 ▲ +13.7% | $-1.76 — $-1.32 | 21% YoY | 3 |
| Next FY | $-1.51 ▼ -8.2% | $-1.68 — $-1.35 | 5% YoY | 3 |
Latest Reports
NEUTRAL
8-K
3/10
Acumen Pharmaceuticals reported Q1 2026 results with a net loss of $20.7M ($0.33/share), narrower than the $28.8M loss (
May 12, 2026
NEUTRAL
PRESS-RELEASE
5/10
Acumen Pharmaceuticals reported Q1 2026 EPS of -$0.33 (GAAP) vs consensus of -$0.46, a 28.3% beat, with net loss narrowi
May 12, 2026
MIXED
Press
6/10
Acumen Pharmaceuticals reported its 2025 financial results, showing increased R&D spending and a wider net loss, while m
Mar 26, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $49.5M | ADD |
| Alyeska Investment Group, L.P. | $5.8M | DOUBLED |
| FRANKLIN RESOURCES INC | $5.4M | TRIM |
| VANGUARD CAPITAL MANAGEMENT LLC | $3.6M | — |
| FMR LLC | $2.7M | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 9, 2026 | Fountain Nathan | SELL | $14.3K |
| Jun 3, 2026 | RA CAPITAL | A | $0.00 |
| Jun 3, 2026 | RA CAPITAL | A | $0.00 |
| Jun 3, 2026 | Drapkin Kimberlee | A | $0.00 |
| Jun 3, 2026 | Drapkin Kimberlee | A | $0.00 |
Reddit Sentiment
60°
Warm
Bearish
Neutral
Bullish
38 institutional holders with $77.5M total value (32,869,385 shares) as of 2026-Q1. Top holders: RA, Alyeska, FRANKLIN. Net buying activity: 9 institutions added/increased vs 3 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 20,992,669 | $49.5M | 63.9% | ADD +40.6% |
| 2 | Alyeska Investment Group, L.P. | 2,454,754 | $5.8M | 7.5% | DOUBLED +161.3% |
| 3 | FRANKLIN RESOURCES INC | 2,305,096 | $5.4M | 7.0% | TRIM -25.1% |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 1,506,277 | $3.6M | 4.6% | — |
| 5 | FMR LLC | 1,157,346 | $2.7M | 3.5% | TRIM -42.9% |
| 6 | Hudson Bay Capital Management LP | 968,940 | $2.3M | 2.9% | ADD +33.6% |
| 7 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 601,476 | $1.4M | 1.8% | — |
| 8 | TWO SIGMA INVESTMENTS, LP | 530,812 | $1.3M | 1.6% | TRIM -28.2% |
| 9 | RENAISSANCE TECHNOLOGIES LLC | 473,946 | $1.1M | 1.4% | TRIM -27.6% |
| 10 | BANK OF AMERICA CORP /DE/ | 320,216 | $755.7K | 1.0% | ADD +33.3% |
| 11 | GOLDMAN SACHS GROUP INC | 206,683 | $487.8K | 0.6% | — |
| 12 | VANGUARD FIDUCIARY TRUST CO | 199,226 | $470.2K | 0.6% | — |
| 13 | MARSHALL WACE, LLP | 192,889 | $455.2K | 0.6% | DOUBLED +822.6% |
| 14 | BlackRock, Inc. | 178,326 | $420.8K | 0.5% | TRIM -40.2% |
| 15 | STATE STREET CORP | 151,728 | $358.1K | 0.5% | ADD +51.5% |
| 16 | MORGAN STANLEY | 144,584 | $341.2K | 0.4% | TRIM -42.7% |
| 17 | DIMENSIONAL FUND ADVISORS LP | 119,756 | $281.8K | 0.4% | DOUBLED +144.1% |
| 18 | Point72 Asset Management, L.P. | 67,375 | $159.0K | 0.2% | ADD +85.3% |
| 19 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 56,000 | $132.2K | 0.2% | — |
| 20 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 55,900 | $131.9K | 0.2% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | ADD | 14,932,063 | 20,992,669 | +40.6% | $49.5M | 2026-Q1 |
| Alyeska Investment Group, L.P. | DOUBLED | 939,603 | 2,454,754 | +161.3% | $5.8M | 2026-Q1 |
| FMR LLC | TRIM | 2,027,497 | 1,157,346 | -42.9% | $2.7M | 2026-Q1 |
| Hudson Bay Capital Management LP | ADD | 725,000 | 968,940 | +33.6% | $2.3M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | ADD | 240,152 | 320,216 | +33.3% | $755.7K | 2026-Q1 |
| MARSHALL WACE, LLP | DOUBLED | 20,907 | 192,889 | +822.6% | $455.2K | 2026-Q1 |
| STATE STREET CORP | ADD | 100,178 | 151,728 | +51.5% | $358.1K | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | DOUBLED | 49,062 | 119,756 | +144.1% | $281.8K | 2026-Q1 |
| Point72 Asset Management, L.P. | ADD | 36,365 | 67,375 | +85.3% | $159.0K | 2026-Q1 |
| OMERS ADMINISTRATION Corp | ADD | 22,454 | 28,600 | +27.4% | $67.5K | 2026-Q1 |
| GROUP ONE TRADING LLC | TRIM | 4,752 | 1,475 | -69.0% | $3.5K | 2026-Q1 |
| CWM, LLC | TRIM | 147 | 87 | -40.8% | $205.00 | 2026-Q1 |
| CWM, LLC | NEAR_EXIT | 744 | 147 | -80.2% | — | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 584,292 | 423,100 | -27.6% | $892.7K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 199,446 | 143,221 | -28.2% | $302.2K | 2025-Q4 |
| GROUP ONE TRADING LLC | TRIM | 7,798 | 4,752 | -39.1% | $10.0K | 2025-Q4 |
| FRANKLIN RESOURCES INC | TRIM | 3,077,039 | 2,305,096 | -25.1% | $3.9M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 246,588 | 584,292 | +137.0% | $999.1K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 147,009 | 213,729 | +45.4% | $365.5K | 2025-Q3 |
| BlackRock, Inc. | TRIM | 291,957 | 174,690 | -40.2% | $298.7K | 2025-Q3 |
| UBS Group AG | TRIM | 94,422 | 30,841 | -67.3% | $52.7K | 2025-Q3 |
| PNC FINANCIAL SERVICES GROUP, INC. | TRIM | 4,948 | 3,080 | -37.8% | $5.3K | 2025-Q3 |
| HRT FINANCIAL LP | TRIM | 31,427 | 14,014 | -55.4% | $23.00 | 2025-Q3 |
| CWM, LLC | NEAR_EXIT | 4,136 | 744 | -82.0% | $1.00 | 2025-Q3 |
| STATE STREET CORP | NEAR_EXIT | 521,206 | 106,678 | -79.5% | $123.7K | 2025-Q2 |
9 unique insiders with 21 transactions. Net insider value: -$21.1K ($0.00 bought, $21.1K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 9, 2026 | Fountain Nathan B | Director | SELL | 6,400 | $2.23 | $14.3K |
| Jun 3, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | AWARD | 35,500 | — | — |
| Jun 3, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | AWARD | 53,250 | — | — |
| Jun 3, 2026 | Drapkin Kimberlee C | Director | AWARD | 35,500 | — | — |
| Jun 3, 2026 | Drapkin Kimberlee C | Director | AWARD | 53,250 | — | — |
| Jun 3, 2026 | Fountain Nathan B | Director | AWARD | 35,500 | — | — |
| Jun 3, 2026 | Fountain Nathan B | Director | AWARD | 53,250 | — | — |
| Jun 3, 2026 | Stalfort John A III | Director | AWARD | 35,500 | — | — |
| Jun 3, 2026 | Porter Derrell | Director | AWARD | 53,250 | — | — |
| Jun 3, 2026 | Porter Derrell | Director | AWARD | 35,500 | — | — |
| Jun 3, 2026 | Stoppel Laura | Director | AWARD | 35,500 | — | — |
| Jun 3, 2026 | Ives Jeffrey L. | Director | AWARD | 35,500 | — | — |
| Jun 3, 2026 | Stalfort John A III | Director | AWARD | 53,250 | — | — |
| Jun 3, 2026 | Golumbeski George | Director | AWARD | 53,250 | — | — |
| Jun 3, 2026 | Golumbeski George | Director | AWARD | 35,500 | — | — |
| Jun 3, 2026 | Ives Jeffrey L. | Director | AWARD | 53,250 | — | — |
| Jun 3, 2026 | Stoppel Laura | Director | AWARD | 53,250 | — | — |
| Mar 16, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | AWARD | 6,060,606 | $3.30 | $20.0M |
| Mar 6, 2026 | Meisner Derek M | Chief Legal Officer & Corp Sec | EXERCISE | 2,090 | $1.85 | $3.9K |
| Mar 6, 2026 | Meisner Derek M | Chief Legal Officer & Corp Sec | SELL | 2,090 | $3.26 | $6.8K |
| Feb 27, 2026 | Meisner Derek M | Chief Legal Officer & Corp Sec | EXERCISE | 9,406 | $1.85 | $17.4K |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 4.3/10.
NEUTRAL
8-K
3/10
Acumen Pharmaceuticals reported Q1 2026 results with a net loss of $20.7M ($0.33/share), narrower th
May 12, 2026
NEUTRAL
PRESS-RELEASE
5/10
Acumen Pharmaceuticals reported Q1 2026 EPS of -$0.33 (GAAP) vs consensus of -$0.46, a 28.3% beat, w
May 12, 2026
NEUTRAL
S-3
5/10
Acumen Pharmaceuticals filed an S-3 shelf registration to register the resale of up to 10,833,331 sh
Mar 26, 2026
MIXED
6/10
Acumen Pharmaceuticals reported its 2025 financial results, showing increased R&D spending and a wid
Mar 26, 2026
NEUTRAL
4/10
Acumen Pharmaceuticals announced it will report its Q4 and full-year 2025 financial results on March
Mar 19, 2026
MIXED
6/10
Acumen Pharmaceuticals (ABOS) announced a $35.75 million private placement at $3.30 per share, led b
Mar 16, 2026
Current analyst consensus: Strong Buy (92% buy). Based on 12 analysts: 6 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$7.40 mean target
+212.2% upside
Strong Buy (1.00)
$4.00 Low
$10.00 High
| Metric | Value |
|---|---|
| Current Price | $2.37 |
| Target Low | $4.00 |
| Target Mean | $7.40 |
| Target Median | $8.00 |
| Target High | $10.00 |
| # Analysts | 5 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.41 | $-0.49 | $-0.32 | 40.4% | +11.9% | 1↑ 0↓ | $0.0B | 0.0% | 3 |
| Next Q 2026-09-30 |
$-0.42 | $-0.51 | $-0.33 | 3.8% | +3.8% | 1↑ 0↓ | $0.0B | 0.0% | 3 |
| Current FY 2026-12-31 |
$-1.58 | $-1.76 | $-1.32 | 20.8% | +13.7% | 2↑ 0↓ | $0.0B | 0.0% | 3 |
| Next FY 2027-12-31 |
$-1.51 | $-1.68 | $-1.35 | 4.9% | -8.2% | 1↑ 0↓ | $0.0B | 0.0% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.405 | |
| 7d ago | $-0.422 | +0.017 |
| 30d ago | $-0.460 | +0.055 |
| 60d ago | $-0.460 | +0.055 |
| 90d ago | $-0.460 | +0.055 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 26, 2026 | BTIG | REITERATE | Buy | Buy |
| Mar 16, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Jan 27, 2026 | BTIG | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 5 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 6 | 5 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 6 | 5 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 6 | 5 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 6 | 5 | 1 | 0 | 0 | 92% | |
| Jan 1, 2026 | 6 | 5 | 1 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
60°
Warm
Bearish
Neutral
Bullish
1 mentions
1 bullish
0 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Feb 12, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
May 12, 2026
earnings
Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights
<p>NEWTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=3zunWdg53cpXYGJOymmNegYsexqjb5FdCrmk5Czf7zaFc
May 12, 2026
earnings_calendar
ABOS Q1 2026 Earnings Scheduled — 2026-05-12
May 11, 2026
earnings_calendar
ABOS Q1 2026 Earnings Scheduled — 2026-05-11
May 7, 2026
other
Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference
<p align="left">NEWTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=BHonimD9qP4wrg7AG5_ifTx2JSDqsy92
May 5, 2026
earnings
Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026
<p>NEWTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=wWeyqc9r5OEatBpFhZ1VtUZJyrRBpFS8XGzntVfkMvUgV
Mar 26, 2026
earnings
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights
<p>NEWTON, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=FfNp0mqT1Cqp0dSmsZb6xAiEgOXHXEofxnY_aoDHbI
Mar 26, 2026
earnings_calendar
ABOS Q4 2025 Earnings After Market Close — 2026-03-26
Mar 19, 2026
earnings
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026
<p>NEWTON, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=QY6bOSvufPuHQcHM7jPVjF6XaA3MS7AyrLMbEB7MCJw
Mar 16, 2026
offering
Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio
<p>NEWTON, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=B43QySpFz4N8XMLyVUtTXsRSjG58xnCJBQN04wZcWL
Mar 10, 2026
other
Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
<p>NEWTON, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=miSn7hFmX2ega561eKdQK2XZ2_4AXkf35nv8tNKbXvP